PT-141, known by its generic name bremelanotide and sold under the brand name Vyleesi, is an injectable peptide drug approved by the FDA for treating low sexual desire in premenopausal women. Unlike older sexual-dysfunction medications that work on blood flow, PT-141 acts in the brain, targeting receptors in the hypothalamus that influence desire itself. Its unusual origin story, its mechanism, and its real-world track record all deserve a closer look than the marketing pitch provides.
From Tanning Peptide to Sexual Medicine
PT-141 was not designed from scratch to treat low libido. It is a modified version of melanotan II, a synthetic peptide originally developed in the 1990s at the University of Arizona as a way to darken skin without UV exposure. During early human testing of melanotan II, researchers noticed an unexpected side effect: spontaneous erections in male volunteers. That finding redirected research toward sexual function, and a truncated, cyclic version of the peptide was eventually designated PT-141 and advanced into clinical trials for both male erectile dysfunction and female sexual desire disorder.1PubMed. Melanocortin peptide therapeutics: historical milestones, clinical studies and commercialization
The male erectile-dysfunction program was eventually shelved after concerns about blood-pressure effects in early trials, but the female sexual-desire program continued. In June 2019, the FDA approved bremelanotide for the treatment of acquired, generalized hypoactive sexual desire disorder (HSDD) in premenopausal women.2PubMed. Bremelanotide: First Approval
How PT-141 Works in the Brain
Most drugs for sexual dysfunction target the genitals. Medications for erectile dysfunction, for example, relax blood vessels in the penis to improve blood flow. PT-141 takes a fundamentally different approach: it works in the central nervous system.
Bremelanotide activates melanocortin receptors, a family of receptors found throughout the body. At the doses used therapeutically, the most relevant target is the melanocortin 4 receptor, or MC4R, which is concentrated in a part of the hypothalamus called the medial preoptic area. This brain region is deeply involved in sexual motivation. When PT-141 binds to MC4R neurons there, it triggers increased release of dopamine, a neurotransmitter strongly linked to wanting and reward. In animal models, this dopamine surge translates directly into increased sexual motivation.3PubMed. The neurobiology of bremelanotide for the treatment of hypoactive sexual desire disorder in premenopausal women
The distinction matters practically. Because PT-141 works through desire pathways rather than arousal mechanics, it does not simply produce a physical genital response. It is meant to increase the subjective feeling of wanting sexual activity, which is what people with HSDD report losing.
What HSDD Actually Is
Hypoactive sexual desire disorder is defined as persistently low sexual desire that causes personal distress or difficulty in relationships. The key word is “distress.” Many people have naturally low interest in sex and are perfectly content. HSDD only applies when the lack of desire is bothering the person experiencing it, and when it represents a change from their previous baseline rather than a lifelong pattern.
The FDA approval specifically covers acquired, generalized HSDD in premenopausal women. “Acquired” means the low desire developed after a period of normal desire, and “generalized” means it is not limited to a specific partner or situation.4Journal of Women’s Health. Safety Profile of Bremelanotide Across the Clinical Development Program PT-141 is not approved for postmenopausal women, for men, or for low desire caused by medications, relationship problems, or other medical conditions. In practice, some clinicians prescribe it off-label for populations outside the approved indication, but the clinical evidence base is built around premenopausal women.
What the Phase 3 Trials Actually Found
The pivotal evidence for PT-141 came from the RECONNECT program, which consisted of two parallel phase 3 trials enrolling over 1,200 premenopausal women with HSDD. Participants self-injected either bremelanotide or placebo before anticipated sexual activity for 24 weeks. The trials measured two primary endpoints: change in sexual desire scores and change in distress related to low desire.
On both measures, bremelanotide beat placebo by a statistically significant margin. Across the integrated data from both trials, desire scores increased by 0.35 points more than placebo, and distress scores dropped by 0.33 points more than placebo.5PubMed Central. Bremelanotide for the Treatment of Hypoactive Sexual Desire Disorder: Two Randomized Phase 3 Trials These are modest effect sizes on their respective rating scales, and whether they translate into a meaningful real-world difference has been debated. A critical review in the Drug and Therapeutics Bulletin noted that bremelanotide did not produce a statistically significant increase in the number of satisfying sexual events compared with placebo, calling into question how much patients actually feel the benefit.6PubMed. Bremelanotide and flibanserin for low sexual desire in women: the fallacy of regulatory precedent
That said, the improvements were consistent across subgroups. Analyses from the RECONNECT data showed that bremelanotide worked across different age brackets, body weights, BMI ranges, and testosterone levels. It also worked regardless of whether women were using hormonal contraceptives, though the effect on distress was clearer than the effect on desire in the hormonal-contraceptive subgroup.7PubMed. Prespecified and Integrated Subgroup Analyses from the RECONNECT Phase 3 Studies of Bremelanotide
For women who continued into a 52-week open-label extension, the improvements in desire and distress were sustained, and no new safety concerns emerged.8PubMed Central. Long-Term Safety and Efficacy of Bremelanotide for Hypoactive Sexual Desire Disorder That durability is worth knowing about, since tolerance and waning effects are common worries with any on-demand medication.
Dosage and How It Is Used
Bremelanotide is given as a subcutaneous injection, similar to how many people inject insulin. The approved dose is 1.75 mg, self-administered in the abdomen or thigh about 45 minutes before anticipated sexual activity. It is not a daily medication. You use it only when you want it, which is a practical advantage for some people and a barrier for others who dislike needles.
Prescribing guidelines cap use at one dose per 24-hour period and no more than eight doses per month. If you have been using it for eight weeks and feel no benefit, the recommendation is to stop.9Annals of Pharmacotherapy. Bremelanotide: New Drug Approved for Treating Hypoactive Sexual Desire Disorder Those limits are driven partly by safety (particularly concerning blood pressure) and partly because there is no evidence that using it more frequently works better.
One practical advantage is that bremelanotide has no clinically significant interaction with alcohol, which matters because sexual activity and social drinking often overlap. It also does not interact meaningfully with most other medications, though anyone on blood-pressure drugs should discuss use with their prescriber given the cardiovascular profile described below.
Side Effects Worth Knowing About
Nausea is the dominant side effect, and it is common enough that anyone considering PT-141 should go in prepared. In the phase 3 trials, 40% of women taking bremelanotide experienced nausea, compared with about 1% on placebo. The nausea typically kicked in around 30 minutes after injection, lasted a median of about two and a half hours, and was mild to moderate in roughly 98% of cases. It tended to come and go unpredictably across doses rather than worsening over time. Among women who used an anti-nausea medication, the recurrence rate on subsequent doses dropped substantially. Despite the high nausea rate, only about 8% of participants stopped the drug because of it.5PubMed Central. Bremelanotide for the Treatment of Hypoactive Sexual Desire Disorder: Two Randomized Phase 3 Trials
Other commonly reported side effects include flushing, headache, and injection-site reactions. Some women developed focal skin darkening (hyperpigmentation), a reminder of the drug’s tanning-peptide lineage. That hyperpigmentation tended to show up with repeated dosing and was more pronounced in earlier studies that used daily dosing schedules rather than the approved on-demand approach.
Blood Pressure and Heart Rate
Bremelanotide causes a small, transient rise in blood pressure. In a dedicated ambulatory blood-pressure monitoring study, the approved 1.75 mg dose raised systolic blood pressure by about 3 mmHg above placebo in the first four hours after dosing, with a similar rise in diastolic pressure. These peaks typically lasted less than 15 minutes. Heart rate actually decreased by roughly 4 to 5 beats per minute during the same window, likely a reflexive response to the blood-pressure bump.10PubMed Central. Usefulness of ambulatory blood pressure monitoring to assess the melanocortin receptor agonist bremelanotide
For most healthy premenopausal women, a transient 3-point rise in blood pressure is trivial. But the FDA labeling carries a warning against use in people with uncontrolled hypertension or cardiovascular disease, and the drug is not recommended for anyone at elevated cardiovascular risk. The blood-pressure effects were a significant reason the earlier intranasal formulation (which delivered higher doses) was ultimately abandoned for the lower-dose subcutaneous approach.
PT-141 and Male Erectile Dysfunction
Even though PT-141 is only FDA-approved for women, much of its early clinical history involved men. The original observations of spontaneous erections during melanotan II testing led to dedicated erectile-dysfunction trials. Early results were genuinely interesting: melanocortin receptor agonists appeared capable of triggering erections even without sexual stimulation, including in men who did not respond to standard PDE5 inhibitors like sildenafil or tadalafil.11PubMed Central. Novel Emerging Therapies for Erectile Dysfunction
A small clinical study tested low-dose intranasal PT-141 combined with sildenafil and found that the combination produced a significantly stronger erectile response than sildenafil alone, with no increase in adverse events.12Urology. Co-administration of low doses of intranasal PT-141, a melanocortin receptor agonist, and sildenafil to men with erectile dysfunction results in an enhanced erectile response The idea of a centrally acting drug that complements the peripheral vascular mechanism of PDE5 inhibitors has obvious appeal, especially for the estimated 30-40% of men who do not respond adequately to sildenafil-type drugs alone.
As of now, bremelanotide is not approved for male erectile dysfunction, though the manufacturer has initiated new clinical programs exploring combination formulations of bremelanotide with a PDE5 inhibitor specifically for men who do not respond to standard ED treatment. Whether those programs will lead to an approved product remains to be seen. In the meantime, some men obtain PT-141 through compounding pharmacies or peptide suppliers and use it off-label, a practice that carries the usual risks of unregulated sourcing and dosing without clinical guidance.
How PT-141 Compares to Flibanserin
Before bremelanotide, the only FDA-approved drug for HSDD in premenopausal women was flibanserin (Addyi), approved in 2015. The two drugs are quite different in practice. Flibanserin is a daily oral pill that modulates serotonin and dopamine activity and takes weeks of continuous use to reach its full effect. Bremelanotide is injected on demand and works within about 45 minutes of a single dose. Flibanserin cannot be used with alcohol due to a risk of dangerous drops in blood pressure; bremelanotide does not have that restriction.
Efficacy for both drugs is modest. A critical analysis published in Drug and Therapeutics Bulletin argued that flibanserin led to an average of roughly one additional satisfying sexual experience every two months, while bremelanotide did not achieve a significant increase in that measure at all. The same review raised concerns about the regulatory pathway, noting that bremelanotide’s approval may have benefited from the precedent set by flibanserin’s contentious approval rather than from the strength of its own efficacy data.6PubMed. Bremelanotide and flibanserin for low sexual desire in women: the fallacy of regulatory precedent
That is a fair criticism to keep in mind, but it does not mean PT-141 is worthless. The phase 3 data did show statistically significant improvements in desire and reductions in distress, and some women in those trials clearly felt the drug helped them.5PubMed Central. Bremelanotide for the Treatment of Hypoactive Sexual Desire Disorder: Two Randomized Phase 3 Trials The gap between statistical significance on a questionnaire and a person’s lived experience of improved desire is tricky to measure. Clinical trials in sexual medicine face the additional complication that placebo responses are often large, since the act of participating in a trial focused on one’s sexual health can itself change how people think about and engage with sex.
The MC4R Connection to Appetite and Weight
The melanocortin 4 receptor that PT-141 targets for sexual desire is the same receptor that plays a central role in appetite regulation. MC4R activation promotes satiety, the feeling of fullness that tells you to stop eating. Genetic mutations that knock out MC4R function are one of the most common single-gene causes of severe obesity. This overlap has raised an obvious question: does bremelanotide affect weight?
Data from two early-phase randomized controlled trials examined this. Results from those studies assessed the effects of bremelanotide’s MC4R activation on caloric intake and body weight in obese women.13PubMed Central. Effect of bremelanotide on body weight of obese women: Data from two phase 1 randomized controlled trials The research is still early, and bremelanotide is not being developed as a weight-loss drug, but the biological rationale is sound. Other drugs targeting the melanocortin system, including setmelanotide (approved for rare genetic obesity disorders), have shown that MC4R activation can meaningfully reduce body weight in the right population.
For people using PT-141 as approved for HSDD, any appetite-suppressing effects at the standard on-demand dose are unlikely to produce noticeable weight changes. But the shared receptor biology is a useful reminder that drugs acting in the hypothalamus rarely do just one thing, and it helps explain the nausea that so many users experience.
What PT-141 Is Not
PT-141 has attracted a secondary life in the wellness and biohacking communities, where it is sometimes marketed as a general libido booster or performance enhancer for people without any diagnosed sexual dysfunction. Compounding pharmacies and online peptide vendors sell it in various formulations, including some intended for sublingual or nasal use rather than injection. A few points of caution apply here.
First, the clinical evidence base is specific to premenopausal women with diagnosed HSDD. Using it recreationally in a healthy person with normal sexual desire is extrapolating far beyond what has been studied. Whether it enhances normal desire, rather than restoring diminished desire, is simply not known from controlled trials.
Second, compounded peptides are not subject to the same manufacturing quality controls as FDA-approved drugs. Potency, purity, and sterility can vary dramatically between sources. Reports of contaminated or mislabeled peptides from unregulated suppliers are not uncommon in this market.
Third, the blood-pressure effects, while modest at the approved dose, could be more pronounced at higher doses or in people with undiagnosed cardiovascular risk factors. Without proper screening, someone using PT-141 from an online source might not know they have a condition that makes those transient blood-pressure spikes dangerous.
The drug fills a genuine clinical need for some women whose low desire causes them real distress. Its efficacy is modest, its side-effect profile is manageable for most, and its mechanism of action represents something genuinely novel in sexual medicine. Whether that translates to being worth the cost and the injection for any given person is a conversation best had with a prescriber who can evaluate the full picture rather than with a peptide vendor’s marketing page.